New and updated preclinical and clinical data to be presented by biopharma firms at American Society of Clinical Oncology annual meeting, including: BMS, Candel, Cantargia, Checkmate, Dizal, Elevar, Elevation, Elicio, Exelixis, Galera, Gracell, Harpoon, I-Mab, Immuneering, Immunogen, Immutep, Inovio, Inspirna, Ionctura, Iovance, Ipsen, Karyopharm, Leap, Lytix, Mereo, Mirati, Modra, Novalgen, Noxxon, Oncoinvent, Oncternal, PDS, Pionyr, Protagonist, Roche, Seagen, Springworks, Takeda, Tempest, Xencor, Y-mabs, Zymeworks.